Next Article in Journal
Optimization of Rheological Behaviour and Skin Penetration of Thermogelling Emulsions with Enhanced Substantivity for Potential Application in Treatment of Chronic Skin Diseases
Previous Article in Journal
Effective Therapeutic Delivery and Bioavailability Enhancement of Pioglitazone Using Drug in Adhesive Transdermal Patch
Previous Article in Special Issue
Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled In Silico-Experimental Studies. Part I: Covalent siRNA Nanocarriers
Open AccessReview

Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications

1
Eng4Life Srl, Spin-off Accademico, Via Fiorentino, 32, 83100 Avellino, Italy
2
Dipartimento di Farmacia; Università degli Studi di Salerno, via Giovanni Paolo II, 132 84084 Fisciano (SA), Italy
3
Dipartimento di Ingegneria Industriale; Università degli Studi di Salerno, via Giovanni Paolo II, 132 84084 Fisciano (SA), Italy
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(8), 360; https://doi.org/10.3390/pharmaceutics11080360
Received: 8 July 2019 / Revised: 21 July 2019 / Accepted: 23 July 2019 / Published: 24 July 2019
(This article belongs to the Special Issue Drug Delivery of siRNA Therapeutics)
  |  
PDF [1751 KB, uploaded 24 July 2019]
  |  

Abstract

In the last years the rapid development of Nucleic Acid Based Drugs (NABDs) to be used in gene therapy has had a great impact in the medical field, holding enormous promise, becoming “the latest generation medicine” with the first ever siRNA-lipid based formulation approved by the United States Food and Drug Administration (FDA) for human use, and currently on the market under the trade name Onpattro™. The growth of such powerful biologic therapeutics has gone hand in hand with the progress in delivery systems technology, which is absolutely required to improve their safety and effectiveness. Lipid carrier systems, particularly liposomes, have been proven to be the most suitable vehicles meeting NABDs requirements in the medical healthcare framework, limiting their toxicity, and ensuring their delivery and expression into the target tissues. In this review, after a description of the several kinds of liposomes structures and formulations used for in vitro or in vivo NABDs delivery, the broad range of siRNA-liposomes production techniques are discussed in the light of the latest technological progresses. Then, the current status of siRNA-lipid delivery systems in clinical trials is addressed, offering an updated overview on the clinical goals and the next challenges of this new class of therapeutics which will soon replace traditional drugs. View Full-Text
Keywords: NABDs; siRNA; liposomes; clinical trials NABDs; siRNA; liposomes; clinical trials
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Barba, A.A.; Bochicchio, S.; Dalmoro, A.; Lamberti, G. Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications. Pharmaceutics 2019, 11, 360.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top